Literature DB >> 19918272

Pancreatic and psoas abscesses as a late complication of intravesical administration of bacillus Calmette-Guerin for bladder cancer: a case report and review of the literature.

Miguel Alvarez-Múgica, Jesús M Fernández Gómez, Verónica Bulnes Vázquez, Antonio Jalón Monzón, José M Fernández Rodríguez, Laura Rodríguez Robles.   

Abstract

INTRODUCTION: Bacillus Calmette-Guerin (BCG) is a live attenuated strain of Mycobacterium bovis that has been used to treat urothelial carcinoma since 1976, and has been reported to eradicate disease in more than 70% of patients with in situ and stage I disease. To the best of our knowledge, we report the first case of disseminated bacillus Calmette-Guerin infection causing multiple abscesses affecting the pancreatic head and right psoas muscle, diagnosed 5 years after intravesical treatment with bacillus Calmette-Guerin therapy for bladder cancer. CASE
PRESENTATION: An 83-year-old Caucasian man was hospitalized with a 2-month history of back pain, anorexia, generalized weakness and a 47-pound weight loss. He had previously undergone two transurethral resections for high-grade transitional cell carcinoma of the bladder and had received 12 intravesical bacillus Calmette-Guerin instillations without any complications. He complained of abdominal pain in his right flank. A computed tomography scan of the abdomen showed multiple abscesses affecting the pancreatic head and right psoas muscle. Growth of Mycobacterium bovis was determined in cultures of the purulent material obtained by surgical drainage of the abscesses.
CONCLUSIONS: This case illustrates the fact that although intravesical administration of bacillus Calmette-Guerin is generally considered to be safe, it is not exempt from complications and these could appear immediately after treatment or as a delayed complication many years later.

Entities:  

Year:  2009        PMID: 19918272      PMCID: PMC2767134          DOI: 10.4076/1752-1947-3-7323

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


  14 in total

Review 1.  BCG intravesical instillations: recommendations for side-effects management.

Authors:  P Rischmann; F Desgrandchamps; B Malavaud; D K Chopin
Journal:  Eur Urol       Date:  2000       Impact factor: 20.096

2.  Systemic immune response after intravesical instillation of bacille Calmette-Guérin (BCG) for superficial bladder cancer.

Authors:  K Taniguchi; S Koga; M Nishikido; S Yamashita; T Sakuragi; H Kanetake; Y Saito
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

3.  [Panuveitis following intravesical bacille Calmette-Guerin therapy].

Authors:  M Jacob; J Gambrelle; J Fleury; I Durieu; L Kodjikian; N Duquesne; J D Grange
Journal:  J Fr Ophtalmol       Date:  2006-05       Impact factor: 0.818

4.  Mycobacterium bovis infection of an implantable defibrillator following intravesical therapy with bacille Calmette-Guérin.

Authors:  D R Stone; N A Estes; M S Klempner
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

5.  Mycobacterium bovis-BCG infection of the glans penis: a complication of intravesical administration of bacillus Calmette-Guerin.

Authors:  M Ribera; J Bielsa; J M Manterola; M T Fernández; C Ferrándiz
Journal:  Br J Dermatol       Date:  1995-02       Impact factor: 9.302

6.  Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas.

Authors:  U Elsässer-Beile; O Gutzeit; S Bauer; A Katzenwadel; W Schultze-Seemann; U Wetterauer
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

7.  Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.

Authors:  A Böhle; J Gerdes; A J Ulmer; A G Hofstetter; H D Flad
Journal:  J Urol       Date:  1990-07       Impact factor: 7.450

8.  Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.

Authors:  P F Schellhammer; L E Ladaga; M B Fillion
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

Review 9.  Immunotherapy for urological malignancies.

Authors:  Kent G Krejci; Mary A Markiewicz; Eugene D Kwon
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

Review 10.  Ruptured mycotic abdominal aortic aneurysm secondary to Mycobacterium bovis after intravesical treatment with bacillus Calmette-Guérin.

Authors:  Gregory E J Harding; D Kirk Lawlor
Journal:  J Vasc Surg       Date:  2007-07       Impact factor: 4.268

View more
  3 in total

1.  Concurrent granulomatous hepatitis, pneumonitis and sepsis as a complication of intravesical BCG immunotherapy.

Authors:  Vasiliki Delimpoura; Konstantinos Samitas; Ioannis Vamvakaris; Eleftherios Zervas; Mina Gaga
Journal:  BMJ Case Rep       Date:  2013-10-10

2.  Fever of unknown origin and pancytopenia caused by culture-proven delayed onset disseminated bacillus Calmette-Guerin (BCG) infection after intravesical instillation.

Authors:  Pedro Dammert; Ziad Boujaoude; William Rafferty; Jonathan Kass
Journal:  BMJ Case Rep       Date:  2013-04-09

Review 3.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.